Diffuse Sclerosis Medication

  • Author: Robert Stanley Rust Jr, MD, MA; Chief Editor: B Mark Keegan, MD, FRCPC   more...
 
Updated: Feb 3, 2012
 

Medication Summary

The use of methylprednisolone, its indications, and its possible effects have been reviewed in Treatment. Other corticosteroids or intravenous gamma globulin (IVIG) possibly would also prove beneficial during the acute phase of presentation, but no information exists at present upon which to base any but the most general statements concerning these approaches. Whether intravenous corticosteroid therapy should be followed by an oral taper is unclear, although in most instances of recognized Schilderlike disease, such a taper is generally undertaken. No information exists concerning the appropriate length of such a taper or the influence of such a taper on outcome. No information exists concerning the efficacy of immunomodulatory therapy in Schilder disease as defined by the strict 1912-type criteria posed by CM Poser.

Next

Corticosteroids

Class Summary

Have anti-inflammatory properties and cause profound and varied metabolic effects. Corticosteroids modify the body's immune response to diverse stimuli.

View full drug information

Methylprednisolone (Depo-Medrol, Solu-Medrol, Medrol)

 

The initial dose should be administered under close supervision because rare instances of anaphylaxis after initial dose have been reported.

Previous
Proceed to Follow-up
 
 
Contributor Information and Disclosures
Author

Robert Stanley Rust Jr, MD, MA  Thomas E Worrell Jr Professor of Epileptology and Neurology, Co-Director of FE Dreifuss Child Neurology and Epilepsy Clinics, Director, Child Neurology, University of Virginia School of Medicine; Chair-Elect, Child Neurology Section, American Academy of Neurology

Robert Stanley Rust Jr, MD, MA is a member of the following medical societies: American Academy of Neurology, American Epilepsy Society, American Headache Society, American Neurological Association, Child Neurology Society, International Child Neurology Association, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Specialty Editor Board

William J Nowack, MD  Associate Professor, Epilepsy Center, Department of Neurology, University of Kansas Medical Center

William J Nowack, MD is a member of the following medical societies: American Academy of Neurology, American Clinical Neurophysiology Society, American Epilepsy Society, American Medical Electroencephalographic Association, American Medical Informatics Association, and Biomedical Engineering Society

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

Richard J Caselli, MD  Professor, Department of Neurology, Mayo Medical School, Rochester, MN; Chair, Department of Neurology, Mayo Clinic of Scottsdale

Richard J Caselli, MD is a member of the following medical societies: American Academy of Neurology, American Association of Neuromuscular and Electrodiagnostic Medicine, American Medical Association, American Neurological Association, and Sigma Xi

Disclosure: Nothing to disclose.

Selim R Benbadis, MD  Professor, Director of Comprehensive Epilepsy Program, Departments of Neurology and Neurosurgery, Tampa General Hospital, University of South Florida College of Medicine

Selim R Benbadis, MD is a member of the following medical societies: American Academy of Neurology, American Academy of Sleep Medicine, American Clinical Neurophysiology Society, American Epilepsy Society, and American Medical Association

Disclosure: UCB Pharma Honoraria Speaking, consulting; Lundbeck Honoraria Speaking, consulting; Cyberonics Honoraria Speaking, consulting; Glaxo Smith Kline Honoraria Speaking, consulting; Pfizer Honoraria Speaking, consulting; Sleepmed/DigiTrace Honoraria Speaking, consulting

Chief Editor

B Mark Keegan, MD, FRCPC  Assistant Professor of Neurology, College of Medicine, Mayo Clinic; Master's Faculty, Mayo Graduate School; Consultant, Department of Neurology, Mayo Clinic, Rochester

B Mark Keegan, MD, FRCPC is a member of the following medical societies: American Academy of Neurology, American Medical Association, and Minnesota Medical Association

Disclosure: Novartis Consulting fee Consulting; Bionest Consulting fee Consulting

References

  1. Schilder P. Zur Kenntnis der sogenannten diffusen Sklerose. Z Ges Neurol Psychiatr. 1912;10:1-60.

  2. Schilder P. Zur Frage der Encephalitis periaxialis diffusa. Z Ges Neurol Psychiatr. 1913;15:359-76.

  3. Schilder P. Die Encephalitis periaxialis diffusa. Arch Psychiatr. 1924;71:327-356.

  4. Poser CM. Myelinoclastic diffuse sclerosis. In: Handbook of Clinical Neurology. Vol 3. New York, NY: American Elsevier; 1985:419-428.

  5. Poser CM. Diffuse-disseminated sclerosis in the adult. J Neuropathol Exp Neurol. 1957;16:61-78.

  6. Kraus D, Konen O, Straussberg R. Schilder's disease: Non-invasive diagnosis and successful treatment with human immunoglobulins. Eur J Paediatr Neurol. Sep 16 2011;[Medline].

  7. Barbieri F, Filla A, Grossi D, Orefice G, Perretti A, Cirillo S, et al. Clinical and computerized tomographic study of a case of Schilder's disease. Acta Neurol (Napoli). Feb 1982;4(1):57-61. [Medline].

  8. Bielschowsky M, Henneberg R. Uber familiare diffuse Sklerose (Leukodystrophia cerebri progressiva hereditaria). J Psychol Neurol. 1928;36:131-81.

  9. Cala LA, Mastaglia FL. Computerised tomography findings in multiple sclerosis and Schilder's disease. Clin Exp Neurol. 1977;14:229-36. [Medline].

  10. Cotrufo R, Salvati G, Morcaldi L, Giordano GG, Guazzi GC. [What is Schilder's disease? Biological study of an unusual neuro-endocrine process]. Riv Patol Nerv Ment. Apr 1968;89(2):133-52. [Medline].

  11. Dupel-Pottier C. [Diagnostic criteria of borderline forms of multiple sclerosis]. Rev Neurol (Paris). Sep 2001;157(8-9 Pt 2):935-43. [Medline].

  12. Fernández-Jaén A, Martínez-Bermejo A, Gutiérrez-Molina M, López-Martín V, Tendero A, Arcas J, et al. [Schilder's diffuse myelinoclastic sclerosis]. Rev Neurol. Jul 1-15 2001;33(1):16-21. [Medline].

  13. Ferrer I, Fábregves I, Alvarez EF, Vila J. Schilder's disease. A study of the cerebral cortex with Golgi's method. Childs Brain. 1981;8(4):294-8. [Medline].

  14. Fogli A, Schiffmann R, Bertini E. The effect of genotype on the natural history of eIF2B-related leukodystrophies. Neurology. May 11 2004;62(9):1509-17. [Medline].

  15. Foix C, Marie J. La sclerose cerebrale centrolobaire a tendance symetrique. Encephale. 1927;22:81-126.

  16. Fontaine B. [Borderline forms of multiple sclerosis]. Rev Neurol (Paris). Sep 2001;157(8-9 Pt 2):929-34. [Medline].

  17. Haberfeld W, Spieler F. Zur diffusen Sklerose des Hirns und Ruckenmarks. Dtsch Z Nervenheilkd. 1910;40:436-63.

  18. Heubner O. Uber diffuse Hirnsklerose. Charite-Ann. 1897;22:298-310.

  19. Hogan EL, Joseph KC, Hurt JP, Krigman MR. Schilder's diffuse sclerosis: a biochemical and ultrastructural study of myelinoclastic demyelinaton. Acta Neuropathol. 1972;20(2):85-95. [Medline].

  20. Iwanowski L, Jedrzejewska A, Dydyk L. [Transitional form of disseminated and diffuse sclerosis during the period of exacerbation]. Neuropatol Pol. 1972;10(1):79-85. [Medline].

  21. Jankowski K. A case of Schilder's diffuse sclerosis diagnosed clinically schizophrenia. Acta Neuropathol. 1963;2:302-305.

  22. Kotil K, Kalayci M, Köseoglu T, Tugrul A. Myelinoclastic diffuse sclerosis (Schilder's disease): report of a case and review of the literature. Br J Neurosurg. Oct 2002;16(5):516-9. [Medline].

  23. Kurul S, Cakmakçi H, Dirik E, Kovanlikaya A. Schilder's disease: case study with serial neuroimaging. J Child Neurol. Jan 2003;18(1):58-61. [Medline].

  24. Lhermitte F, Escourolle R, Hauw JJ, Gray F, Serdaru M, Lyon-Caen O. [Necrotic aspects of multiple sclerosis and Schilder's disease (author's transl)]. Rev Neurol (Paris). 1981;137(10):589-600. [Medline].

  25. Lumsden CE. Fundamental problems i the pathology of multiple sclerosis and allied demyelinating diseases. Br Med J. 1951;1:1035-1043.

  26. Marbrug O. Die sogenannte 'akute multiple Sklerose' (Encephalomyelitis periaxialis scleroticans). Jahrb Psychiatr Neurol. 1906;27:211-312.

  27. Marie P, Foix C. Triplegie spasmodique, sclerose intracerebrale centrolobaire et symetrique. Rev Neurol. 1913;21:346.

  28. Marks E, Miszczak J. [Case of late form of Schilder's disease]. Neurol Neurochir Pol. Mar-Apr 1972;6(2):301-3. [Medline].

  29. Miyagawa K, Ando S, Seino M, Murofushi K. [An autopsy case of inflammatory diffuse sclerosis (adult case of Schilder's disease)--clinicopathological study (author's transl)]. Seishin Shinkeigaku Zasshi. Dec 1976;78(12):815-28. [Medline].

  30. Norman MG, Waisberg HA, Lowden JA. Progressive deafness and dementia in an 8-year-old boy. J Pediatr. May 1975;86(5):805-9. [Medline].

  31. Pajak B, Stefanko S, Goldsztajn M. [Acute course of Schilder's disease]. Neurol Neurochir Pol. 1971;5(2):233-6. [Medline].

  32. Picard E. Case records of the Massachusetts General Hospital. Case 43-1965. N Engl J Med. Sep 30 1965;273(14):760-7. [Medline].

  33. Poser CM. Disseminated vasculomyelinopathy. A review of the clinical and pathologic reactions of the nervous system in hyperergic diseases. Acta Neurol Scand. 1969;Suppl 37:3-44. [Medline].

  34. Poser CM. Myelinoclastic diffuse and transitional sclerosis. In: Handbook of Clinical Neurology. Vol 9. New York, NY: American Elsevier; 1970:469-84.

  35. Poser CM, Brinar VV. The nature of multiple sclerosis. Clin Neurol Neurosurg. Jun 2004;106(3):159-71. [Medline].

  36. Poser CM, Goutières F, Carpentier MA, Aicardi J. Schilder's myelinoclastic diffuse sclerosis. Pediatrics. Jan 1986;77(1):107-12. [Medline].

  37. Poser CM, Van Bogaert L. Natural history and evolution of the concept of Schilder's diffuse sclerosis. Acta Neurol Scand. 1956;31:285-331.

  38. Tanaka J, Garcia JH, Khurana R. Unusual demyelinating disease. A form of diffuse-disseminated sclerosis. Neurology. Jun 1975;25(6):588-93. [Medline].

  39. Van Bogaert L, De Busscher J. Sur la sclerose inflammatoire de la substance blanche des hemispheres. Rev Neurol. 1939;71:679-701.

  40. Van Gehuchten P, Brucher JM. La forme transitionelle de la sclerose cerebrale diffuse de Schilder. Rev Neurol. 1961;104:108-125.

  41. Vanden Herrewegen M, Chamoles N. [Recent study on the significance of diffuse sclerosis of the Schilder type (1912) in children. 1. Anatomoclinical aspect of a sporadic case]. Acta Neurol Psychiatr Belg. Nov 1968;68(11):837-50. [Medline].

  42. Walker E. Case records of the MGH - leukoencephalitis, diffuse sclerosis (Schilder's disease). N Engl J Med. 1962;266:191-96.

  43. Watanabe I, Muller J. Cavitating "diffuse sclerosis". J Neuropathol Exp Neurol. Jul 1967;26(3):437-55. [Medline].

 
Previous
Next
 
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.